高级搜索
硼替佐米诱导ABCG2 High耐药鼻咽癌细胞高 表达N KG2D 配体的实验研究[J]. 肿瘤防治研究, 2008, 35(11): 761-765. DOI: 10.3971/j.issn.1000-8578.510
引用本文: 硼替佐米诱导ABCG2 High耐药鼻咽癌细胞高 表达N KG2D 配体的实验研究[J]. 肿瘤防治研究, 2008, 35(11): 761-765. DOI: 10.3971/j.issn.1000-8578.510
Induction of Expression of Ligands for NKG2D Receptor in ABCG2 High Nasopharyngeal Carcinoma by Bortezomib[J]. Cancer Research on Prevention and Treatment, 2008, 35(11): 761-765. DOI: 10.3971/j.issn.1000-8578.510
Citation: Induction of Expression of Ligands for NKG2D Receptor in ABCG2 High Nasopharyngeal Carcinoma by Bortezomib[J]. Cancer Research on Prevention and Treatment, 2008, 35(11): 761-765. DOI: 10.3971/j.issn.1000-8578.510

硼替佐米诱导ABCG2 High耐药鼻咽癌细胞高 表达N KG2D 配体的实验研究

Induction of Expression of Ligands for NKG2D Receptor in ABCG2 High Nasopharyngeal Carcinoma by Bortezomib

  • 摘要: 目的 探讨硼替佐米诱导高表达ABCG2 耐药鼻咽癌细胞对Allo2N K细胞杀伤敏感性的机制。方法 利用免疫磁珠技术分离ABCG2 High CNE2/ DDP 细胞及Allo2N K细胞,流式细胞技术检测分离后细胞纯度及经硼替佐米处理前后靶细胞N KG2D 配体表达率,LDH 释放测定法检测经硼替佐米处理前后ABCG2 HighCNE2/ DDP 细胞对Allo2N K细胞的杀伤敏感性。结果 ABCG2 High CNE2/ DDP 细胞分离后ABCG2 表达率为(91. 40 ±2. 32) %, 分选后N K 细胞CD3 - CD16 + CD56 + 细胞的纯度达90 %以上。经硼替佐米处理之后靶细胞MICA、MICB、ULBP1 、ULBP2 、ULBP3 表达率,由药物处理之前的(2. 92 ±0. 33) %、(4. 27 ±0. 33) %、(5. 80 ±0. 62) %、(11. 10 ±3. 15) %、(7. 75 ±1. 14) %分别上升到(17. 52 ±2. 04) %、(12. 53 ±3. 68) %、(15. 24 ±2. 91) %、(62. 02 ±6. 85) %、(35. 69 ±3. 23) %。在效靶比为10∶1 、20∶1 、Allo2N K 细胞对硼替佐米处理前后ABCG2 High CNE2/ DDP 细胞的杀伤率分别为( 15. 32 ±13. 86) %、(27. 26 ±6. 81) %及(35. 06 ±5. 10 ) %、( 52. 34 ±4. 78 ) %。处理前后杀伤率差异有统计学意义( F =26. 03, P = 0. 000) 。结论 硼替佐米通过诱导肿瘤细胞高表达N KG2D 配体(MICA/ B、ULBP123), 使肿瘤细胞对Allo2N K细胞的杀伤敏感性增强。

     

    Abstract: Objective  To investigate the mechanism on the effect s of improving cytotoxic sensitivity of ABCG2 High CNE2/ DDP cells to Allo2N K cells which exerted by bortezomib. Methods  ABCG2 HighCNE2/DDP cells and Allo2N K cells were isolated by magnetic activated cell sorting (MACS) . Flow cytomet ry was used to evaluate the purity of isolated cells and the expression of N KG2D2ligands on target cells be2 fore and af ter incubation with bortezomib. Subsequently, the cytotoxic sensitivity of t reated and un2t reated ABCG2 High CNE2/ DDP cells to Allo2N K cells were measured by LDH releasing assay. Results  The ex2 pressions of ABCG2 in ABCG2 High CNE2/ DDP cells were (91. 40 ±2. 32) %. More than 90 % of isolated N K cells showed tobe CD3 - CD16 + CD56 + cells which would definitely meet the needs of experiment s. The expressions of MICA、MICB、ULBP1 、ULBP2 、ULBP3 on target cells incubated with bortezomib have respectively increased f rom ( 2. 92 ±0. 33) %, ( 4. 27 ±0. 33) %, ( 5. 80 ±0. 62 ) %, ( 11. 10 ±3. 15 ) %, (7. 75 ±1. 14) % to (17. 52 ±2. 04) %、(12. 53 ±3. 68) %、(15. 24 ±2. 91) %、(62. 02 ±6. 85) %、(35. 69 ±3. 23) %. At the E∶T ratio of 10∶1 and 20∶1, the cytotoxic sensitivity of ABCG2 HighCNE2/ DDP cells to Allo2N K cells increased f rom (15. 32 ±13. 86) % and (27. 26 ±6. 81) % in un2t reated groups to (35. 06 ±5. 10) % and (52. 34 ±4. 78) % in bortezomib t reated groups. Data above showed that cytotoxic sensitivity of target cells in each group before and af ter bortezomib t reatment had significant differences ( F = 26. 03 P = 0. 000) . Conclusion  Bortezomib can up2regulate expressions of N KG2D2ligands (MICA/ B、ULBP123 ) in ABCG2 High nasopharyngeal carcinoma cells, which resulted in higher cytotoxic sensitivity to Allo2N K cells.

     

/

返回文章
返回